• Sonuç bulunamadı

Do we need this? And if so – how shall we proceed?

N/A
N/A
Protected

Academic year: 2021

Share "Do we need this? And if so – how shall we proceed?"

Copied!
6
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

Do we need this?

And if so – how shall we proceed?

(2)
(3)

The cheerleading squad for this collaboration/network

Lars Vorland Helse Nord RTF

Oddvar Larsen Helse Nord RTF

Hanne Haukland Helse Nord RTF

Päivi Väre Länsi-Pohja Hospital district

Jari Jokela Lapland Hospital district

Jukka Mattila Lapland Hospital district

Aino-Liisa Oukka Oulu University Hospital district

Veronika Sundström County Council of Norrbotten

Pia Näsvall County Council of Norrbotten

Ulla Isaksson County Council of Norrbotten

(4)
(5)

More meetings?

(6)

Referanslar

Benzer Belgeler

• Bu noktadan hareketle; 1930 yılından önce gelistirilen özel “kıskaç- tipi kalibre” aleti ile (kaliper) vücudun belirli bölgelerinden yapılan deri altı yağ ölçümü

• Bu noktadan hareketle; 1930 yılından önce gelistirilen özel “kıskaç- tipi kalibre” aleti ile (kaliper) vücudun belirli bölgelerinden yapılan deri altı yağ ölçümü

ACC 2014 guideline on management of patients with AF (1) endorses as class 1c recommendation for patients with AF or atrial flutter <48-hour duration and with high risk of

Electrocardiogram simulated by the full reaction-diffusion model at 0.25-mm resolution (black) and by the hybrid model at 1-mm resolution (red online/grey). Tick marks at the

3 hasta brakial pleksus avulziyonu nedeni ile 91u- ~an agn yakmmasl ile ba~vurmu~ olup DREZ ameli- yan sonraSI tiim hastalarda tarn agrl kontrolii saglanml~nr.. Postparaplejik agrl

The power capacity of the hybrid diesel-solar PV microgrid will suffice the power demand of Tablas Island until 2021only based on forecast data considering the

Second, we aimed to evalu- ate the plausible association between scintigraphic results obtained with the MIBI parathyroid scintigraphy in patient groups (having either ectopic

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence